First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

被引：1

作者：

Ku, G. ^{[1
]}

Shen, L. ^{[2
]}

Klempner, S. J. ^{[3
]}

Pan, H. ^{[4
]}

Kratz, J. ^{[5
]}

Liang, X. ^{[6
]}

Deng, Y. ^{[7
]}

Kim, S. ^{[8
]}

Wang, Z. ^{[9
]}

Feller, L. ^{[10
]}

Powderly, J. ^{[11
]}

Dayyani, F. ^{[12
]}

Schneider, R. E. ^{[13
]}

Girda, E. ^{[14
]}

Berlin, J. D. ^{[15
]}

Spencer, K. ^{[16
]}

Nguyen, M. T. ^{[17
]}

Wang, V. ^{[17
]}

Xu, C. ^{[17
]}

Zhu, A. ^{[18
]}

机构：

[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY USA

[2] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China

[3] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA

[4] Zhejiang Univ, Sir Run Run Run Shaw Hosp, Med, Sch Med, Hangzhou, Zhejiang, Peoples R China

[5] Univ Wisconsin, Med, Sch Med & Publ Hlth Med Phys, Madison, WI USA

[6] HuBei Canc Hosp, Med Dept, Wuhan, Peoples R China

[7] Sun Yat Sen Univ, Affiliated Hosp 6, Med, Guangzhou, Guangdong, Peoples R China

[8] Univ Colorado, Med Oncol Dept, UCHlth Canc Care, Ctr Canc, Anschutz Med Campus, Aurora, CO USA

[9] China Med Univ, Med, Affiliated Hosp 1, Shenyang, Peoples R China

[10] Horizon BioAdvance, Med Oncol Dept, Lafayette, LA USA

[11] Carolina BioOncol Inst, Oncol, Huntersville, NC USA

[12] UCI Univ Calif Irvine, Med Dept, Hlth Manchester Pavil, Orange, CA USA

[13] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA

[14] Rutgers Canc Inst New Jersey, Med Oncol Dept, New Brunswick, NJ USA

[15] Vanderbilt Univ, Med Dept, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA

[16] NYU, Med Dept, Langone Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[17] I Mab Biopharma, Res & Dev, San Diego, CA USA

[18] I Mab Biopharma Co Ltd Headquarter, Res & Dev, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2178

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1039P

引用

页码：S631 / S631

页数：1

共 50 条

[31] A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors [J].

Katsuya, Yuki ;

Ikeda, Masafumi ;

Koyama, Takafumi ;

Sato, Jun ;

Okada, Mao ;

Matsubara, Nobuaki ;

Kondoh, Chihiro ;

Mukohara, Toru ;

Watanabe, Kazuo ;

Kotani, Daisuke ;

Ogawa, Yoshimi ;

Taoka, Shose ;

Yamamoto, Noboru .

CANCER SCIENCE, 2025, 116 (04) :1012-1022

[32] First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease [J].

Marron, T. ;

Rosen, S. ;

Orr, D. ;

Powderly, J., II ;

Khaskhely, N. ;

Bonham, L. ;

Nelson, M. ;

Taromino, C. ;

Taylor, D. ;

Kumer, J. ;

Ellmark, P. ;

Fritzell, S. ;

Ambarkhane, S. V. ;

Huebner, D. ;

Alahmadi, A. .

ANNALS OF ONCOLOGY, 2024, 35 :S524-S525

[33] First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer [J].

Sahin, U. ;

Schuler, M. ;

Bauer, S. ;

Krilova, A. ;

Utsch, M. ;

Huber, C. ;

Tuereci, O. .

ANNALS OF ONCOLOGY, 2017, 28

[34] First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors [J].

Papadopoulos, Kyriakos P. ;

Harb, Wael ;

Peer, Cody J. ;

Hua, Qiong ;

Xu, Siying ;

Lu, Haolan ;

Lu, Ni ;

He, Yue ;

Xu, Ting ;

Dong, Ruiping ;

Gong, John ;

Liu, David .

ONCOLOGIST, 2021, 26 (09) :E1514-E1525

[35] GEN1046 (Bispecific Antibody Targeting PD-L1 and 4-1BB): Preclinical Characteristics and Phase 1 Results in Solid Tumors [J].

Kunkel, Maria ;

Muik, Alexander ;

Altintas, Isil ;

Gieseke, Friederike ;

Schodel, Kristina ;

Diken, Mustafa ;

Sette, Angelica ;

Stanganello, Eliana ;

Vascotto, Fulvia ;

Breij, Esther ;

Sasser, Kate ;

Tureci, Ozlem ;

Forssmann, Ulf ;

Ahmadi, Tahamtan ;

Sahin, Ugur .

CANCER SCIENCE, 2023, 114 :1566-1566

[36] AM105: A novel bispecific antibody with Anti 4-1BB affibodies and EGFR antibody [J].

Kim, Dong-Wook ;

Lee, Hyun-Jong ;

Kim, Seong Yeol ;

Yoon, Min ;

Lee, Youngha ;

Hwang, In-Sik ;

Lee, Yoon ;

Kim, Jong-Hoon ;

Lee, Jong-Seo .

CANCER RESEARCH, 2024, 84 (06)

[37] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study [J].

Bai, X. ;

Chen, Y. ;

Liang, X. ;

Wang, H. ;

Sun, Y. ;

Chu, Q. ;

Pan, Y. ;

Cui, J. ;

Fang, J. ;

Zhang, W. ;

Xu, Q. ;

Zhang, J. ;

Liu, X. ;

Dai, G. ;

Kang, L. ;

Li, N. ;

Fang, M. ;

Zhou, H. ;

Liang, T. .

ANNALS OF ONCOLOGY, 2024, 35 (07) :681-682

[38] First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors [J].

Elena Elez, Maria ;

Tabernero, Josep ;

Geary, David ;

Macarulla, Teresa ;

Kang, S. Peter ;

Kahatt, Carmen ;

Soto-Matos Pita, Arturo ;

Fernandez Teruel, Carlos ;

Siguero, Mariano ;

Cullell-Young, Martin ;

Szyldergemajn, Sergio ;

Ratain, Mark J. .

CLINICAL CANCER RESEARCH, 2014, 20 (08) :2205-2214

[39] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors [J].

Koganemaru, S. ;

Yoshizuka, N. ;

Mizuno, S. ;

Hirai, S. ;

Yamamoto, N. .

ANNALS OF ONCOLOGY, 2024, 35 :S531-S531

[40] Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors [J].

Cassier, Philippe A. ;

Borad, Mitesh J. ;

Sharma, Sunil ;

Dubois, Bertrand ;

Caux, Christophe ;

Okano, Fumiyoshi ;

Von Hoff, Daniel D. ;

Blay, Jean-Yves .

CANCER RESEARCH COMMUNICATIONS, 2025, 5 (07) :1119-1128

← 1 2 3 4 5 →